• ABPI Website
  • Media
  • ABPI refreshes its commitment to improve public involvement in research

ABPI refreshes its commitment to improve public involvement in research

Today marks the one-year anniversary of when funders, regulators and research organisations who play an important role in the UK health and social care research signed up to a bold new shared commitment to improve public involvement in research.

We know that patient involvement is fundamental to industry’s commitment to advancing science, delivering medicines, and improving patient outcomes. Richard Torbett, ABPI Chief Executive

Reiterating ABPI’s commitment to the shared goal, ABPI Chief Executive Richard Torbett said:

"We know that patient involvement is fundamental to industry’s commitment to advancing science, delivering medicines, and improving patient outcomes. It’s critical that companies’ work with patients is done in line with the ABPI’s Code of Practice. The ABPI and PMCPA have guidance available to help companies work with patients in a Code-compliant way.

“Whether it’s working with patients on the feasibility and design of clinical trials or making sure study information is available in plain language, only by working with patients can we be sure we are developing medicines that meet their needs.

"This is why ABPI remains committed to embedding patient and public involvement at the heart of research."

ABPI Sourcebook: Working with patients and patient organisations - 2022 sourcebook for industry

PMCPA Social Media Guidance 2023 (including on recruiting patients to clinical trials on social media)

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.